These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
431 related items for PubMed ID: 33462245
1. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, Chen D, Wei J, Ti D, Liu Z, Mei Q, Li X, Dong L, Nie J, Zhang Y, Han W. Nat Commun; 2021 Jan 18; 12(1):409. PubMed ID: 33462245 [Abstract] [Full Text] [Related]
2. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells. You L, Han Q, Zhu L, Zhu Y, Bao C, Yang C, Lei W, Qian W. Front Immunol; 2020 Jan 18; 11():1787. PubMed ID: 32973749 [Abstract] [Full Text] [Related]
3. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma. Shi X, Chen X, Fang B, Ping Y, Qin G, Yue D, Li F, Yang S, Zhang Y. Biomed Pharmacother; 2019 Apr 18; 112():108632. PubMed ID: 30797153 [Abstract] [Full Text] [Related]
6. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M, Errami M, Blanquart C. Clin Epigenetics; 2018 Apr 18; 10():79. PubMed ID: 29946373 [Abstract] [Full Text] [Related]
7. Increased IFNγ+ T Cells Are Responsible for the Clinical Responses of Low-Dose DNA-Demethylating Agent Decitabine Antitumor Therapy. Li X, Zhang Y, Chen M, Mei Q, Liu Y, Feng K, Jia H, Dong L, Shi L, Liu L, Nie J, Han W. Clin Cancer Res; 2017 Oct 15; 23(20):6031-6043. PubMed ID: 28706011 [Abstract] [Full Text] [Related]
8. Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression. Niu C, Li M, Zhu S, Chen Y, Zhou L, Xu D, Li W, Cui J, Liu Y, Chen J. Front Immunol; 2018 Oct 15; 9():617. PubMed ID: 29632540 [Abstract] [Full Text] [Related]
12. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy. Hajari Taheri F, Hassani M, Sharifzadeh Z, Behdani M, Arashkia A, Abolhassani M. IUBMB Life; 2019 Sep 15; 71(9):1259-1267. PubMed ID: 30724452 [Abstract] [Full Text] [Related]